Last Chance to Register for SSLLC’s Genetown 50.
Lot 1 begins closing at 10am (EST). Soft close and popcorn bidding activated.
Nothing interest you in this auction? Check out our auction for next week below.
Surplus Solutions LLC
SSLLC Newsletter
November Newsletter
Bausch and Stroebel AFV1010 Vial and Ampoule Filling Machine
BOC Edwards Lyoflex 2.0 24 sq. ft Stoppering Freeze Dryer
PennTech RW250 Semi-Automatic Vial Washer
Mueller PyroPure Multi-effect (MES) WFI Still
B. Braun Biotech 100L Bioreactor
AB Sciex QTRAP 5500 LC-MS/MS System
Inova Optima SV 125 V Syringe Filler, Unused
Visit us at www.ssllc.com to view all available inventory.
Got surplus equipment?
Got surplus equipment? Buying and selling your equipment is now simplified. Our trained sales experts are ready and waiting to guide you through the process of selling your surplus equipment. It can be as simple as 1-2-3-4.
Click the link below and tell us about your surplus assets and a member of our team will be in touch shortly.
Or Call 401.526.0055 and speak to a Sales Representative.
The New SSLLC.COM
a { text-decoration:none }
|
New Auctions in 2014
Surplus Solutions LLC is excited to announce our new two part Auction of Lantheus Medical Imaging which is taking place in February 2014. It will be a two part auction with a preview that starts February 24th. It will include Late Model Laboratory and Pilot Manufacturing Equipment…
Visit our auction page for more information…
Seasons Greetings from Surplus Solutions LLC
|
San Diego Complete Biotech Facility Closure 12/18
a { text-decoration:none }
|
UPDATE Online Auction of Sangart a BioPharma Facility 12/18
a { text-decoration:none }
|
Online Auction of Sangart a BioPharma GLP/GMP Facility Dec 18th
Surplus Solutions, LLC will be holding an online auction of Sangart a GLP/GMP BioPharma facility starting December 18th-20th…
“Sangart is a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen delivery. During more than 30 years of extensive research, Sangart has refined the pegylation of human hemoglobin to create a proprietary molecule, MP4, with the ability to perfuse oxygen deprived tissues and carry oxygen through the circulatory system to prevent and treat ischemia (oxygen deprivation of tissues).
Our product platform is based on the MP4 molecule, an investigational biopharmaceutical designed to enhance the perfusion and oxygenation of ischemic tissues”
Please visit our website to Register…
Auction Features
Class 100 Filling Suite:
|
  |
Class 10,000 Processing Suites:
- American Alloy Portable Vessels—18, 20, 25 and 35 liters
- Allegheny Bradford Portable Vessels—150, 300 and 400 liters
- Feldmeier 60 liter Portable Vessel
- (5) Cherry Burrell Rotary Lobe Pumps
- (3) Top Flo Sanitary Centrifugal Pumps on carts
- MECO Still, 300 gallons per hour, 5 Columns, 3000 hrs of use
- Filtrine 5 Ton Chiller
- (3) Pall Integrity Testers
- CES Blast Freezer
- Thermo/Revco Freezer Farm, -20 to -80, upright and chest
- Numerous SS Tables, carts, cages, Masterflex Pumps, consummables
- Drexel SLT22 Forklift, side shift and swing shift mast, 36 Volt charger
Complete GLP Analytical Laboratory equipment available as well with Agilent LC’s and GC’s, Dionex ICS 5000, AKTA FPLC’s, and Biocold Stability Chambers.
*Please note as of 12/5 the dates have been changed to Dec 18-20th. Thank you.
IN THE NEWS: Cubist wins expanded approval for GI drug
Cubist Pharmaceuticals Inc. has won an expanded Food and Drug Administration approval for its gastrointestinal surgery drug Entereg.
The drug helps speed recovery for patients after bowel resection for benign or malignant colorectal or small bowel disease. The new approval means the drug could also be used for patients following a complex surgery called radical cystectomy, which involves removing a part of the bowel in order reconstruct the urinary tract. Entereg is the first and only FDA-approved agent for this use.
The Lexington, Mass.-based company (Nasdaq: CBST)is positioning the drug as one that can save hospitals money.
“Delayed GI recovery is one of the most common causes of prolonged hospital stays in patients undergoing major abdominopelvic surgery. We are pleased that doctors will have the option to help speed GI recovery for appropriate patients who have undergone surgeries that included a bowel resection,” Steven Gilman, Executive Vice President of Research and Development and Chief Scientific Officer of Cubist, said in a statement. “At Cubist, we are committed to improving patient outcomes within the hospital setting, and enabling patients to leave the hospital sooner through the use of therapeutics that help put them on the path to good health.”
Entereg was first approved by the FDA in 2008, when it was owned by Adolor Corp. Adolor agreed to be acquired by Cubist in October 2011. Cubist grew revenues for the drug to $40.2 million in 2012 from $32 million in 2011. Cubist has said Entereg sales will hit $100 million by 2017.
Entereg is available only for short-term use in hospitalized patients, because of the potential increased risk of myocardial infarction.
Visit www.ssllc.com for your equipment needs.
Surplus Solutions 